Viral suppression in adolescents on antiretroviral treatment: review of the literature and critical appraisal of methodological challenges

Rashida A Ferrand, Datonye Briggs, Jane Ferguson, Martina Penazzato, Alice Armstrong, Peter MacPherson, David A Ross, Katharina Kranzer, Rashida A Ferrand, Datonye Briggs, Jane Ferguson, Martina Penazzato, Alice Armstrong, Peter MacPherson, David A Ross, Katharina Kranzer

Abstract

Objective: Medication adherence is often suboptimal for adolescents with HIV, and establishing correct weight-based antiretroviral therapy dosing is difficult, contributing to virological failure. This review aimed to determine the proportion of adolescents achieving virological suppression after initiating ART.

Methods: MEDLINE, EMBASE and Web of Science databases were searched. Studies published between January 2004 and September 2014 including ≥50 adolescents taking ART and reporting on the proportion of virological suppressed participants were included.

Results: From a total of 5316 potentially relevant citations, 20 studies were included. Only eight studies reported the proportion of adolescents that were virologically suppressed at a specified time point. The proportion of adolescents with virological suppression at 12 months ranged from 27 to 89%.

Conclusion: Adolescent achievement of HIV virological suppression was highly variable. Improved reporting of virological outcomes from a wider range of settings is required to support efforts to improve HIV care and treatment for adolescents.

Keywords: Adolescentes; Adolescents; HIV; VIH; adolescents; suppression virologique; supresión virológica; virological suppression.

© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.

References

    1. World Health Organization . Adolescent HIV Testing, Counselling and Care: Implementation Guidance for Health Providers and Planners. World Health Organization: Geneva, Switzerland, 2014.
    1. World Health Organization . Health for the World's Adolescents: A Second Chance in the Second Decade. World Health Organization: Geneva, Switzerland, 2014.
    1. World Health Organization . Global Update on HIV Treatment 2013: Results, Impact and Opportunities. World Health Organization: Geneva, 2013.
    1. Hanghøj S, Boisen KA. Self‐reported barriers to medication adherence among chronically ill adolescents: a systematic review. J Adolesc Health 2014: 54: 121–138.
    1. Modi AC, Pai AL, Hommel KA et al Pediatric self‐management: a framework for research, practice, and policy. Pediatrics 2012: 129: e473–e485.
    1. Mofenson LM, Cotton MF. The challenges of success: adolescents with perinatal HIV infection. J Int AIDS Soc 2013: 16: 18650.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Med 2009: 6: e1000097.
    1. Wells GA, Shea B, O'Connell D et al The Newcastle‐Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta‐Analyses. O.H.R.I.: Ottawa, ON, 2007.
    1. Bakeera‐Kitaka S, McKellar M, Snider C et al Antiretroviral therapy for HIV‐1 infected adolescents in Uganda: assessing the impact on growth and sexual maturation. J Pediatric Infect Dis 2008: 3: 97–104.
    1. Evans D, Menezes C, Mahomed K et al Treatment outcomes of HIV‐infected adolescents attending public‐sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses 2013: 29: 892–900.
    1. Nglazi MD, Kranzer K, Holele P et al Treatment outcomes in HIV‐infected adolescents attending a community‐based antiretroviral therapy clinic in South Africa. BMC Infect Dis 2012: 12: 21.
    1. Nachega JB, Hislop M, Nguyen H et al Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009: 51: 65–71.
    1. Mutwa PR, Boer KR, Rusine J et al Long‐term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV‐1‐infected children and adolescents in Rwanda. Pediatric Infect Dis J 2014: 33: 63–69.
    1. Sebunya R, Musiime V, Kitaka SB, Ndeezi G. Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic. AIDS Res Ther 2013: 10: 25.
    1. Van Cutsem G, Knight L, Abrahams M et al Outcomes in children, adolescent, youth and adults on ART in Khayelitsha. abstract no THPE0170. XVIII International AIDS Conference 2010, Vienna, Austria.
    1. Murphy DA, Belzer M, Durako SJ et al Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005: 159: 764–770.
    1. Chandwani S, Koenig LJ, Sill AM, Abramowitz S, Conner LC, D'Angelo L. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health 2012: 51: 242–251.
    1. Van Dyke RB, Patel K, Siberry GK et al Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr 2011: 57: 165–173.
    1. Flynn PM, Rudy BJ, Lindsey JC et al Long‐term observation of adolescents initiating HAART therapy: three‐year follow‐up. AIDS Res Hum Retroviruses 2007: 23: 1208–1214.
    1. de Mulder M, Yebra G, Navas A et al High drug resistance prevalence among vertically HIV‐infected patients transferred from pediatric care to adult units in Spain. PLoS ONE 2012: 7: e52155.
    1. Sabin CA, Smith CJ, d'Arminio MA et al Response to combination antiretroviral therapy: variation by age ‐ The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Aids 2008: 22: 1463–1473.
    1. Dollfus C, Le Chenadec J, Faye A et al Long‐term outcomes in adolescents perinatally infected with HIV‐1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). Clin Infect Dis 2010: 51: 214–224.
    1. Judd A, Doerholt K, Tookey PA et al Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996‐2006: planning for teenage and adult care. Clin Infect Dis 2007: 45: 918–924.
    1. Zhao Y, Mu W, Harwell J et al Drug resistance profiles among HIV‐1‐infected children experiencing delayed switch and 12‐month efficacy after using second‐line antiretroviral therapy: an observational cohort study in rural China. J Acquir Immune Defic Syndr 2011: 58: 47–53.
    1. Chokephaibulkit K, Kariminia A, Oberdorfer P et al Characterizing HIV manifestations and treatment outcomes of perinatally infected adolescents in Asia. Pediatric Infect Dis J 2014: 33: 291–294.
    1. Shet A, Neogi U, Sahoo PN, De Costa A Effectiveness of first‐line antiretroviral therapy and acquired drug resistance among HIV‐1‐infected children in India. Pediatric Infect Dis J 2013: 32: e227–e229.
    1. Cruz ML, Cardoso CA, Darmont MQ et al Viral suppression and adherence among HIV‐infected children and adolescents on antiretroviral therapy: results of a multicenter study. J Pediatr (Rio J) 2014: 90: 563–571.
    1. Santos Cruz ML, Freimanis Hance L, Korelitz J et al Characteristics of HIV infected adolescents in Latin America: results from the NISDI pediatric study. J Trop Pediatr 2011: 57: 165–172.
    1. The PLOS Medicine Editors Observational Studies: Getting Clear about Transparency. PLoS Med (2014) 11, e1001711.
    1. Field N, Cohen T, Struelens MJ et al Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME‐ID): an extension of the STROBE statement. Lancet Infect Dis 2014: 14: 341–352.
    1. Grimsrud AT, Cornell M, Egger M, Boulle A, Myer L Impact of definitions of loss to follow‐up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFU. J Clin Epidemiol 2013: 66: 1006–1013.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa